Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35506567)

  • 1. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability.
    Wang H; Li ZW; Ou Q; Wu X; Nagasaka M; Shao Y; Ou SI; Yang Y
    Cancer Med; 2022 Jul; 11(13):2541-2549. PubMed ID: 35506567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
    Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
    Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer.
    Guo Y; Guo XL; Wang S; Chen X; Shi J; Wang J; Wang K; Klempner SJ; Wang W; Xiao M
    Oncologist; 2020 Nov; 25(11):e1671-e1680. PubMed ID: 32627883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project.
    Bridgewater J; Jiao X; Parimi M; Flach C; Stratford J; Kamburov A; Schmitz AA; Zong J; Reeves JA; Keating K; Bruno A; Fellous M; Pereira MB; Bazhenova L
    Cancer Treat Res Commun; 2022; 33():100623. PubMed ID: 36041373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.
    Vaňková B; Vaněček T; Ptáková N; Hájková V; Dušek M; Michal M; Švajdler P; Daum O; Daumová M; Michal M; Mezencev R; Švajdler M
    Genes Chromosomes Cancer; 2020 Oct; 59(10):562-568. PubMed ID: 32427409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?
    Vegivinti CTR; Gonzales Gomez C; Syed M; Ferrell M; Cheng S; Singhi A; Saeed A; Sahin IH
    Expert Opin Biol Ther; 2023; 23(7):595-601. PubMed ID: 37318031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.
    Westphalen CB; Krebs MG; Le Tourneau C; Sokol ES; Maund SL; Wilson TR; Jin DX; Newberg JY; Fabrizio D; Veronese L; Thomas M; de Braud F
    NPJ Precis Oncol; 2021 Jul; 5(1):69. PubMed ID: 34285332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer.
    Madison RW; Hu X; Ramanan V; Xu Z; Huang RSP; Sokol ES; Frampton GM; Schrock AB; Ali SM; Ganesan S; De S
    JCO Precis Oncol; 2022 May; 6():e2100477. PubMed ID: 35584350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
    Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
    Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTRK fusion in Japanese colorectal adenocarcinomas.
    Yamashiro Y; Kurihara T; Hayashi T; Suehara Y; Yao T; Kato S; Saito T
    Sci Rep; 2021 Mar; 11(1):5635. PubMed ID: 33707574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
    Forschner A; Forchhammer S; Bonzheim I
    J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.
    Carethers JM; Jung BH
    Gastroenterology; 2015 Oct; 149(5):1177-1190.e3. PubMed ID: 26216840
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Bang H; Lee MS; Sung M; Choi J; An S; Kim SH; Lee SE; Choi YL
    Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
    Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
    Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling of gene fusion involving targetable genes in Chinese gastric cancer.
    Liu ZH; Zhu BW; Shi M; Qu YR; He XJ; Yuan HL; Ma J; Li W; Zhao DD; Liu ZC; Wang BM; Wang CY; Tao HQ; Ma TH
    World J Gastrointest Oncol; 2022 Aug; 14(8):1528-1539. PubMed ID: 36160735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screening.
    Delaye M; Ibadioune S; Julié C; Marin C; Peschaud F; Lupinacci R; Vacher S; Ahmanache L; Antonio S; Schnitzler A; Buecher B; Mariani P; Allory Y; Grati OT; Emile JF; Neuzillet C; Bièche I
    Eur J Cancer; 2022 Jul; 170():85-90. PubMed ID: 35598360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.